AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8846803 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists (combined analysis)
Number of subjects: 0
Study 2167369 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium
Number of subjects: 20
Study 2167369 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate
Number of subjects: 20
Study 2167369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 323834 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing doses of frusemide (Group A)
Number of subjects: 19
Study 323834 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide in a fixed dose of 80 mg daily and increasing doses of spironolactone (Group B)
Number of subjects: 19
Study 31667987 — intervention group
Group type: EXPERIMENTAL
Intervention: LUS-guided follow-up (n=61)
Number of subjects: 123
Study 31667987 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up (n=62)
Number of subjects: 123
Study 28317660 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal with DebioJect™ (IDJ)
Number of subjects: 66
Study 28317660 — intervention group
Group type: COMPARATOR
Intervention: Standard intradermal with classical needle (IDS)
Number of subjects: 66
Study 28317660 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular with classical needle (IM)
Number of subjects: 66
Study 28317660 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (IDJ, IDS, IM)
Number of subjects: 66
Study 25290743 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) with music during CWR exercise tests
Number of subjects: 39
Study 25290743 — intervention group
Group type: COMPARATOR
Intervention: Control group (listening to music during CWR exercise tests)
Number of subjects: 39
Study 24089511 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP‐1 (0.8 pmol/kg ⋅ min) continuous 24‐h infusion (prolonged)
Number of subjects: 10
Study 24089511 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP‐1 (0.8 pmol/kg ⋅ min) two 4.5‐h infusions separated by 20 h (intermittent)
Number of subjects: 10
Study 24089511 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP‐1 (0.8 pmol/kg ⋅ min) 4.5‐h infusion (acute)
Number of subjects: 10
Study 24089511 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline (placebo)
Number of subjects: 10
Study 24089511 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP‐1 (0.8 pmol/kg ⋅ min) acute and intermittent regimens
Number of subjects: 10
Study 22292365 — intervention group
Group type: EXPERIMENTAL
Intervention: Central monitoring method
Number of subjects: 0
Study 22292365 — intervention group
Group type: COMPARATOR
Intervention: Chart review method
Number of subjects: 0
Study 22292365 — intervention group
Group type: COMPARATOR
Intervention: Literature study method
Number of subjects: 0
Study 22292365 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous reporting method
Number of subjects: 0
Study 19542037 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive school-based program
Number of subjects: 1714
Study 19542037 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 1714
Study 17540209 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/d)
Number of subjects: 38
Study 17540209 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment for heart failure
Number of subjects: 38
Study 15376463 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times daily for 6 months
Number of subjects: 36
Study 15376463 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Orlistat)
Number of subjects: 36
Study 11136838 — intervention group
Group type: EXPERIMENTAL
Intervention: ABMT arm (high-dose chemotherapy plus autologous bone marrow transplantation)
Number of subjects: 311
Study 11136838 — intervention group
Group type: COMPARATOR
Intervention: Control arm (standard chemotherapy)
Number of subjects: 311
Study 9665112 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice-yearly deworming with 500 mg mebendazole
Number of subjects: 30
Study 9665112 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-yearly deworming with 500 mg mebendazole
Number of subjects: 30
Study 9665112 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 30
Study 1927238 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2.5 mg)
Number of subjects: 8
Study 1927238 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (0.5 mg)
Number of subjects: 8
Study 1927238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1927238 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2.5 mg) with warning signal
Number of subjects: 8
Study 1927238 — intervention group
Group type: COMPARATOR
Intervention: Placebo with warning signal
Number of subjects: 8
Study 6749348 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg once daily
Number of subjects: 14
Study 6749348 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 50 mg once daily
Number of subjects: 14
Study 6749348 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorothiazide 500 mg twice daily
Number of subjects: 14
Study 6749348 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorothiazide 500 mg once daily
Number of subjects: 14
Study 6749348 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorothiazide 1000 mg once daily
Number of subjects: 14
Study 6749348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31972618 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP/CHROMO
Number of subjects: 1905
Study 31972618 — intervention group
Group type: COMPARATOR
Intervention: SC
Number of subjects: 1905
Study 30903410 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone allograft with gentamicin (8 mg gentamicin/gram bone solution for 1 hour)
Number of subjects: 50
Study 30903410 — intervention group
Group type: COMPARATOR
Intervention: Bone allograft without gentamicin
Number of subjects: 50
Study 29059253 — intervention group
Group type: EXPERIMENTAL
Intervention: e-POCT
Number of subjects: 3192
Study 26893605 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-use supplementary food (RUSF)
Number of subjects: 84
Study 26893605 — intervention group
Group type: COMPARATOR
Intervention: Corn-soy blend (CSB)
Number of subjects: 84
Study 25550296 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect moxibustion for 30 minutes daily, five sessions weekly for 4 weeks
Number of subjects: 30
Study 25550296 — intervention group
Group type: COMPARATOR
Intervention: Dressing application only
Number of subjects: 30
Study 22434716 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 217
Study 22434716 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous immunotherapy (SCIT)
Number of subjects: 217
Study 20556805 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary bone marrow-derived cell (BMC) transplantation
Number of subjects: 725
Study 18686554 — intervention group
Group type: EXPERIMENTAL
Intervention: Training health workers using the IMCI module 'Counsel the mother'
Number of subjects: 375
Study 18686554 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 375
Study 15805205 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1000 mg administered intravenously five minutes before skin incision)
Number of subjects: 21
Study 15805205 — intervention group
Group type: COMPARATOR
Intervention: Control group (tranexamic acid not administered)
Number of subjects: 21
Study 12891221 — intervention group
Group type: COMPARATOR
Intervention: Topical diclofenac (65 mg)
Number of subjects: 0
Study 12891221 — intervention group
Group type: COMPARATOR
Intervention: Oral diclofenac (93 mg)
Number of subjects: 0
Study 12891221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10554529 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of sodium selenite
Number of subjects: 0
Study 10554529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9167113 — intervention group
Group type: EXPERIMENTAL
Intervention: Epalrestat (150 mg/day)
Number of subjects: 31
Study 9167113 — intervention group
Group type: COMPARATOR
Intervention: Control (no epalrestat)
Number of subjects: 31
Study 9167113 — intervention group
Group type: EXPERIMENTAL
Intervention: Epa(+) and Epa(-) groups
Number of subjects: 31
Study 1447639 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed formula (Nidal HA)
Number of subjects: 256
Study 1447639 — intervention group
Group type: COMPARATOR
Intervention: Adapted formula (Nidina)
Number of subjects: 256
Study 3515950 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan (2 gm single dose)
Number of subjects: 36
Study 3515950 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (three 2 gm doses)
Number of subjects: 36
Study 30454668 — intervention group
Group type: EXPERIMENTAL
Intervention: NP+FI
Number of subjects: 3816
Study 30454668 — intervention group
Group type: COMPARATOR
Intervention: UC
Number of subjects: 3816
Study 26362564 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg dextromethorphan plus 100 mg sitagliptin
Number of subjects: 20
Study 26362564 — intervention group
Group type: COMPARATOR
Intervention: 100 mg sitagliptin alone
Number of subjects: 20
Study 26362564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24363555 — intervention group
Group type: EXPERIMENTAL
Intervention: Waon therapy
Number of subjects: 20
Study 24363555 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 22677305 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac-K 12.5 mg liquid capsules
Number of subjects: 42
Study 22677305 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac-K 12.5 mg tablets
Number of subjects: 42
Study 20923065 — intervention group
Group type: EXPERIMENTAL
Intervention: Covering letters signed by three researchers
Number of subjects: 750
Study 20923065 — intervention group
Group type: COMPARATOR
Intervention: Covering letters signed by one researcher
Number of subjects: 750
Study 17875557 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance rehabilitation to improve motor and sensory strategies (Group 1)
Number of subjects: 44
Study 17875557 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance rehabilitation to improve motor strategy (Group 2)
Number of subjects: 44
Study 17875557 — intervention group
Group type: COMPARATOR
Intervention: Treatments not specifically aimed at improving balance (Group 3)
Number of subjects: 44
Study 17875557 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities‐specific Balance Confidence and Dizziness Handicap Inventory (self-administered tests)
Number of subjects: 44
Study 15956995 — intervention group
Group type: COMPARATOR
Intervention: Antipsychotic-free patients
Number of subjects: 78
Study 15956995 — intervention group
Group type: COMPARATOR
Intervention: Patients receiving atypical antipsychotics
Number of subjects: 78
Study 15956995 — intervention group
Group type: COMPARATOR
Intervention: Patients receiving typical antipsychotics
Number of subjects: 78
Study 15956995 — intervention group
Group type: COMPARATOR
Intervention: Patients with schizophrenia/schizophreniform disorder
Number of subjects: 78
Study 15956995 — intervention group
Group type: COMPARATOR
Intervention: Patients with depression
Number of subjects: 78
Study 15956995 — intervention group
Group type: COMPARATOR
Intervention: Patients with bipolar disorder
Number of subjects: 78
Study 15956995 — intervention group
Group type: COMPARATOR
Intervention: Patients with other psychoses
Number of subjects: 78
Study 12074399 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported confidence to achieve and maintain an erection (IIEF)
Number of subjects: 799
Study 12074399 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and absence of sexual activity over the last 4 weeks
Number of subjects: 799
Study 12074399 — intervention group
Group type: EXPERIMENTAL
Intervention: Health complaints, depression, IPSS score, absence of physical activity
Number of subjects: 799
Study 10432132 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal progesterone cream (20 mg progesterone daily)
Number of subjects: 102
Study 10432132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 10432132 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal progesterone cream
Number of subjects: 102
Study 8846247 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol drops
Number of subjects: 37
Study 8846247 — intervention group
Group type: COMPARATOR
Intervention: Placebo drops
Number of subjects: 37
Study 1838075 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg etodolac twice daily
Number of subjects: 61
Study 1838075 — intervention group
Group type: COMPARATOR
Intervention: 500 mg naproxen twice daily
Number of subjects: 61
Study 7452872 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-brain irradiation (2,000 rads in two weeks)
Number of subjects: 323
Study 7452872 — intervention group
Group type: COMPARATOR
Intervention: No brain treatment (control)
Number of subjects: 323
Study 30638797 — intervention group
Group type: EXPERIMENTAL
Intervention: qHPV vaccine
Number of subjects: 3006
Study 30638797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3006
Study 29078810 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved oxygen system (including standardized equipment package, training of staff, infrastructure support, quality improvement activities)
Number of subjects: 3
Study 29078810 — intervention group
Group type: COMPARATOR
Intervention: Pulse oximetry alone (Phase 1)
Number of subjects: 3
Study 29078810 — intervention group
Group type: EXPERIMENTAL
Intervention: Full improved oxygen system package (Phase 2)
Number of subjects: 3
Study 24736951 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based preventive intervention (Rochester Resilience Project)
Number of subjects: 203
Study 23408728 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone SR (32 mg/day) plus bupropion SR (360 mg/day)
Number of subjects: 1496
Study 23408728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1496
Study 21861896 — intervention group
Group type: EXPERIMENTAL
Intervention: Hwangryunhaedoktang
Number of subjects: 0
Study 21861896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19588525 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg dutasteride once daily for 3 months (BPH)
Number of subjects: 25
Study 19588525 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 mg dutasteride once daily for 3 months (BPH)
Number of subjects: 25
Study 19588525 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg dutasteride once daily for 3 months (PCa)
Number of subjects: 25
Study 19588525 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 mg dutasteride once daily for 3 months (PCa)
Number of subjects: 25
Study 17383309 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-based distal protection
Number of subjects: 39
Study 17383309 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 15102998 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose epinephrine (0.1 mg/kg)
Number of subjects: 68
Study 15102998 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose epinephrine (0.01 mg/kg)
Number of subjects: 68
Study 15102998 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose epinephrine (0.1 mg/kg) in asphyxia cases
Number of subjects: 68
Study 15102998 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose epinephrine (0.01 mg/kg) in asphyxia cases
Number of subjects: 68
Study 11452712 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg extended-release (ER) buspirone tablets
Number of subjects: 18
Study 11452712 — intervention group
Group type: COMPARATOR
Intervention: 15 mg immediate-release (IR) buspirone tablets
Number of subjects: 18
Study 9741514 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 0
Study 8067750 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid containing magnesium and aluminum hydroxide
Number of subjects: 10
Study 8067750 — intervention group
Group type: COMPARATOR
Intervention: Pefloxacin without antacid
Number of subjects: 10
Study 3134359 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg three times daily for six weeks)
Number of subjects: 201
Study 3134359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 3134359 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 201
Study 29041997 — intervention group
Group type: EXPERIMENTAL
Intervention: Video
Number of subjects: 311
Study 29041997 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based module (WBM)
Number of subjects: 311
Study 29041997 — intervention group
Group type: COMPARATOR
Intervention: Caregiver confidence
Number of subjects: 311
Study 29041997 — intervention group
Group type: COMPARATOR
Intervention: School days missed
Number of subjects: 311
Study 29041997 — intervention group
Group type: COMPARATOR
Intervention: Nights with difficulty sleeping
Number of subjects: 311
Study 29041997 — intervention group
Group type: COMPARATOR
Intervention: Days before return to a normal diet
Number of subjects: 311
Study 29041997 — intervention group
Group type: COMPARATOR
Intervention: Workdays missed
Number of subjects: 311
Study 28219129 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (1.3 MAC for 40 min)
Number of subjects: 90
Study 28219129 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (1.3 MAC for 40 min)
Number of subjects: 90
Study 28219129 — intervention group
Group type: COMPARATOR
Intervention: Propofol (3.5‐4.0 μg/ml target controlled infusion)
Number of subjects: 90
Study 25770310 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 40
Study 25770310 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 40
Study 24329412 — intervention group
Group type: EXPERIMENTAL
Intervention: Character attributions
Number of subjects: 212
Study 24329412 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention attributions
Number of subjects: 212
Study 24329412 — intervention group
Group type: EXPERIMENTAL
Intervention: Controllability attributions
Number of subjects: 212
Study 20498215 — intervention group
Group type: EXPERIMENTAL
Intervention: ASspiMRI‐a (MRI inflammation score)
Number of subjects: 214
Study 20498215 — intervention group
Group type: EXPERIMENTAL
Intervention: mSASSS (structural damage score)
Number of subjects: 214
Study 20498215 — intervention group
Group type: EXPERIMENTAL
Intervention: BASMI (spinal mobility index)
Number of subjects: 214
Study 20498215 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease duration < or = 3 years
Number of subjects: 214
Study 20498215 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease duration > 3 years
Number of subjects: 214
Study 19294776 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical-grade heroin under medical supervision
Number of subjects: 0
Study 19294776 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 16178130 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetylpyridinium chloride (CPC) mouthrinse
Number of subjects: 139
Study 16178130 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 139
Study 14504152 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine patch (1 mg x cm(‐2), applied 30 min before venepuncture)
Number of subjects: 32
Study 14504152 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch (applied 30 min before venepuncture)
Number of subjects: 32
Study 10922431 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA plus intracoronary stent placement
Number of subjects: 650
Study 10922431 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA plus abciximab therapy
Number of subjects: 650
Study 10922431 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA plus intracoronary stent placement plus abciximab therapy
Number of subjects: 650
Study 10922431 — intervention group
Group type: COMPARATOR
Intervention: PTCA alone
Number of subjects: 650
Study 8555493 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-10 (rhIL-10)
Number of subjects: 9
Study 8555493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 1907769 — intervention group
Group type: COMPARATOR
Intervention: Xeroform
Number of subjects: 30
Study 1907769 — intervention group
Group type: EXPERIMENTAL
Intervention: Duoderm
Number of subjects: 30
Study 1907769 — intervention group
Group type: EXPERIMENTAL
Intervention: Biobrane
Number of subjects: 30
Study 7002524 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (new antihypertensive drug)
Number of subjects: 14
Study 30585438 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic polymorphism rs295137 (T allele) near SPATS2L
Number of subjects: 604
Study 30585438 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic polymorphism rs2626393 (C allele) near ASB3
Number of subjects: 604
Study 28904010 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D3) 4000 IU/day for 12 weeks
Number of subjects: 254
Study 28904010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 26714385 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 15 mg daily for 12 months
Number of subjects: 24
Study 26714385 — intervention group
Group type: COMPARATOR
Intervention: Control (no tolvaptan)
Number of subjects: 24
Study 24029881 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning tutorial
Number of subjects: 14
Study 20506333 — intervention group
Group type: EXPERIMENTAL
Intervention: SES
Number of subjects: 904
Study 20506333 — intervention group
Group type: COMPARATOR
Intervention: PES
Number of subjects: 904
Study 20506333 — intervention group
Group type: EXPERIMENTAL
Intervention: SES (nondiabetic)
Number of subjects: 904
Study 20506333 — intervention group
Group type: COMPARATOR
Intervention: PES (nondiabetic)
Number of subjects: 904
Study 20506333 — intervention group
Group type: EXPERIMENTAL
Intervention: SES (diabetic)
Number of subjects: 904
Study 20506333 — intervention group
Group type: COMPARATOR
Intervention: PES (diabetic)
Number of subjects: 904
Study 19120322 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear acupuncture
Number of subjects: 207